Abeona Therapeutics Inc.
- ABEO
- NASDAQ
- Biotechnology
- Gene & Cell Therapy (Rare Disease)
$4.60
Today +4.31%Quote Oct 20, 2026, 07:04 PM UTC
−20.83%over the last month
Max drawdown −25.1%From 1-month high −24.2%3 months −32.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
226
Founded
1974
Market value
$263.0M
Quote Oct 20
Floor
$4.55
1.0% below price
Resistance
$4.83
4.9% above price
Price vs analyst targets
9 analysts
Lowest target
$15.00Highest target
$21.00
$15.00Highest target
$21.00
- Price $4.60
- Average target $17.67
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 284% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ABEOPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free